High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease
-
- Hisauchi Itaru
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Ishikawa Tetsuya
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Ayaori Makoto
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College
-
- Uto-Kondo Harumi
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College Department of Bioscience in Daily Life, Nihon University
-
- Koshikawa Yuri
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Ukaji Tomoaki
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Nakamura Hidehiko
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Mizutani Yukiko
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Taguchi Isao
- Department of Cardiology, Dokkyo Medical University, Saitama Medical Center
-
- Nakajima Takatomo
- Division of Cardiology, Saitama Cardiovascular Respiratory Center
-
- Mutoh Makoto
- Division of Cardiology, Saitama Cardiovascular Respiratory Center
-
- Ikewaki Katsunori
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College
この論文をさがす
抄録
<p>Aim: We examined the impact of baseline high-density lipoprotein cholesterol efflux capacity (CEC) on major cardiac adverse events (MACE) in patients with coronary artery disease (CAD) during a long-term secondary prevention. </p><p>Method: CEC was measured using a cell-based efflux system in (3)[H]-cholesterol-labeled J774 macrophages in apolipoprotein B-depleted plasma between January 2011 and January 2013. Patients with CAD were divided into 2 groups as a boundary CEC value of 1: 0.19 ≤ CEC ＜1 (impaired CEC group, mean CEC of 0.76±0.16, n=136), and 1 ≤ CEC ≤ 2.08 (enhanced CEC group, 1.20±0.19, n=44). MACE, comprised the incidence of cardiac death, non-fatal myocardial infarction, and any revascularizations (RV) without restenosis approximately 1 year after vascularization, was retrospectively investigated at September 2019. Impact of enhanced CEC on MACE among 22 variables was examined by applying a Cox proportional hazard model. </p><p>Result: The frequency of MACE in impaired CEC group (16.9%, mean observational interval of 2111±888 days) was significantly higher than that in enhanced CEC group (2.3%, 2,252±685, p=0.013), largely driven by the significantly higher RV incidence (14.0 % versus 2.3 %, p=0.032). Enhancement of CEC was the significant predictor of MACE (hazard ratio: 0.11; 95% CI: 0.013-0.879; p=0.038). </p><p>Conclusion: A baseline CEC level of more than 1 in patients with CAD brought favorable long-term clinical outcomes, suggesting that CEC is a useful prognostic and therapeutic surrogate for secondary prevention of CAD. </p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 28 (7), 696-702, 2021-07-01
一般社団法人 日本動脈硬化学会
